Compare Build A Bear Workshop Inc (BBW) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs Moderna, Inc. — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $461.88M), while Moderna, Inc. trades at $60.25 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 52.4× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BBW | MRNA | |
|---|---|---|
Market Cap | $461.88M | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $81.80 |
52-Week Low | $29.84 | $22.36 |
Enterprise Value | $561.32M | $20.33B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
